| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000407806 |
| ISSN: | 1665-2681 |
| Autores: | Chinchilla López, Paulina1 Qi, Xingshun2 Yoshida, Eric M3 Méndez Sánchez, Nahum1 |
| Instituciones: | 1Fundación Clínica Médica Sur, Unidad de Investigación de Hígado, Ciudad de México. México 2General Hospital of Shenyang Military Area, Department of Gastroenterology, Shenyang, Liaoning. China 3Vancouver General Hospital, Division of Gastroenterology, Vancouver, Columbia Británica. Canadá |
| Año: | 2017 |
| Periodo: | May-Jun |
| Volumen: | 16 |
| Número: | 3 |
| Paginación: | 328-330 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferonbased therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Gastroenterología, Oncología, Hepatitis C, Terapia antiviral, Factores de riesgo, Carcinoma hepatocelular |
| Keyword: | Medicine, Gastroenterology, Oncology, Pharmacology, Hepatitis C, Antiviral therapy, Risk factors, Hepatocellular carcinoma |
| Texto completo: | Texto completo (Ver PDF) |
